Bausch Health Companies Inc. (NYSE:BHC) traded at $27.78 at last check on Tuesday, May 04, made a downturn move of -11.58% on its previous day’s price.
Looking at the stock we see that its previous close was $31.42 and the beta (5Y monthly) reads 1.72 with the day’s price range being $27.68 – 30.06. The company has a trailing 12-month PE ratio of 0. In terms of its 52-week price range, BHC has a high of $34.8 and a low of $14.86. The company’s stock has gained about -0.91% over that past 30 days.
Bausch Health Companies Inc. has a market cap of $11.34 Billion and is expected to release its quarterly earnings report on May 04, 2021. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the BHC stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of $0.94, with the EPS growth for the year raised at $4.39 for 2021 and $4.87 for next year. These figures represent 0.1% and 0.11% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $2.06 Billion, with a low of $1.98 Billion and a high of $2.13 Billion. The median projection represents growth adding up to 2.3% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2021 is expected to hit $8.66 Billion, or +7.8% up from figures reported last year.
On the other hand, looking at the outlook for the BHC stock, short term indicators assign the stock an average of Hold, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of 50% Buy.
Based on estimates by 16 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 5 have rated the Bausch Health Companies Inc. (BHC) stock as a Hold, while 10 rate it as a Buy. None analyst(s) rate it as outperform while 1 of them rated it as underperform, whereas none suggest the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the BHC stock currently stands at 0, and the most recent price level today is -9.19% off its SMA20 and -11.99% from its 50-day simple moving average. The RSI (14) is pointing at 35.08 while the volatility over the past week is 4.87% and drops to 3.2% over the past one month. The beta value is 1.72, while the average true range (ATR) is currently pointing at 1.05. The average price target for the stock over the next 12 months is $36.86, with the estimates having a low of $27 and a high of $55. These price ends are -2.81% and +97.98% off the today’s price level respectively, although investors could be excited at the prospect of a +33.19% if the BHC share price touches on the median price of $37.
Let’s briefly compare Bausch Health Companies Inc. (BHC) stock to its peers. We find that today’s price change of -11.58% and +83.1% over the past 12 months for BHC competes that of Teva Pharmaceutical Industries Ltd (TEVA), which has seen its stock price fall -5.03% in the latest trading session and is +6.61% over the last one year. Another of its peers Dr. Reddy’s Laboratories Ltd (RDY) has dropped -2.51% today, and was +39.48% up over the past year, while Bridgebio Pharma Inc (BBIO) is also down -11.58% yet, while its price remains in the green at 83.1% over the same period. Bausch Health Companies Inc. has a P/E ratio of 0 compared to Teva Pharmaceutical Industries Ltd’s 0 and Dr. Reddy’s Laboratories Ltd’s 40.83. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -1.21% and -0.62%, respectively, in early deals.
Coming back to Bausch Health Companies Inc. (NYSE:BHC), we note that the average 3-month trading volume was 5.22 Million, while that of the preceding 10-day period stands at 1.95 Million. Current shares outstanding are 355.66 Million.
According to data from Thomson Reuters, insiders hold 2.94% of the company’s shares while institutions hold 69.48%. The data shows that short shares as of April 14, 2021, stood at 15.75 Million at a short ratio of 3.97. This represents a 4.43% short interest in shares outstanding on April 14, 2021. Shares short rose in April from the previous month at 14.98 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +51.06% up in year-to-date price movement.